Apolipoprotein E kinetics: Influence of insulin resistance and type 2 diabetes

International Journal of Obesity

Volumn 26, Issue 11, 2002, Pages 1451-1458

  Bach Ngohou, K ^a,b   Ouguerram, K ^a   Nazih, H ^a,b   Maugere P ^a   Ripolles Piquer, B ^a   Zair Y ^a   Frenais R ^a   Krempf, M ^a   Bard, Jean Marie ^a,b,c  

^a HÔTEL DIEU   (France)

^b UFR Pharmacie   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

Apolipoprotein E; Hypertriglyceridemia; Insulin resistance syndrome; Kinetic studies; Obesity; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN E; DEUTERIUM; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LEUCINE; LIPOPROTEIN LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BODY MASS; CATABOLISM; CLINICAL ARTICLE; COMPUTER PROGRAM; COMPUTER SIMULATION; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISOTOPE LABELING; KINETICS; LIPOPROTEIN METABOLISM; LIVER CLEARANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL;

ADULT; AGED; APOLIPOPROTEINS E; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; LIPASE; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; OBESITY;

EID: 0036866906     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802149     Document Type: Article

References (47)

1. Semenkovich CF, Heinecke JW. The mystery of diabetes and atherosclerosis. Time for a new plot. Diabetes 1997; 46: 327-334.
2. Van Gaal LF, Zhang A, Steijaert MM, Leeuw IH. Human obesity: From lipid abnormalities to lipid oxidation. Int J Obes Relat Metab Disord 1995; 19: 521-526.
3. Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA, Speizer FE. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990; 132: 501-513.
4. Colditz GA, Willet WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in woman. Ann Intern Med 1995; 122: 481-486.
5. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
6. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
7. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
8. Gregg RE, Brewer HB Jr. The role of apolipoprotein E and lipoprotein receptors in modulating the in vivo metabolism of apolipoprotein B-containing lipoproteins in human. Clin Chem 1988; 34: B28-B32.
9. Mahley RW, Ji Z-S. Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 1999; 40:1-16.
10. Zhang SH, Reddick RL, Piedrarita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992; 258: 468-472.
11. Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apoE deficient mice created by homologous recombination in ES cell. Cell 1992; 71: 343-353.
12. Blum CB. Dynamics of apoE metabolism in humans. J Lipid Res 1982; 23: 1308-1316.
13. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Brewer HB. Familial apolipoprotein E deficiency. J Clin Invest 1986; 78: 1206-1219.
14. Gregg RE, Zech LA, Schaefer EJ, Brewer HB Jr. Type III hyperlipoproteinemia: Defective metabolism of an abnormal apolipoprotein E. Science 1981; 211: 584-585.
15. Maugeais C, Tietge UJF, Tsukamoto K, Glick JM, Rader DJ. Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice. J Lipid Res 2000; 41: 1673-1679.
16. Mensenkamp AR, Jong MC, Van Goor H, Van Luyn MJA, Bloks V, Havinga R, Voshol PJ, Hofker MH, Van Dijk KW, Havekes LM, Kuipers F. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem 1999; 274: 35711-35718.
17. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630.
18. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloïd peptides. Nat Genet 1996; 14: 55-61.
19. Havel RJ, Kane JP, Kashyap ML. Interchange of apolipoproteins between chylomicrons and high density lipoproteins during alimentary lipemia in man. J Clin Invest 1973; 52: 32-38.
20. Gibson JC, Brown WV. Effect of lipoprotein lipase and hepatic triglycerides lipase activity on the distribution of apolipoprotein E among the plasma lipoproteins. Atherosclerosis 1988; 75: 45-55.
21. Jeppensen J, Hollenbeck CB, Zhou MY, Coulston AM, Jones C, Chen YD, Reaven GM. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity and postprandial lipemia. Arterioscler Thromb Vasc Biol 1995; 15: 320-324.
22. Bard JM, Charles MA, Juhan-Vague I, Vague P, André P, Safar M, Fruchart JC, Eschwège E, on behalf of the BIGPRO study group. Accumulation of triglycerides-rich lipoproteins in subjects with abdominal obesity. The biguanides and the prevention of the risk of obesity (BIGPRO)1-study. Arterioscler Thromb Vasc Biol 2001; 21: 407-414.
23. Howard BV. Lipoprotein in diabetes mellitus. J Lipid Res 1987; 28: 613-628.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatic model assessment: Insulin resistance and cell function from fasting glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
25. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J Lipid Res 1981; 22: 339-358.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
27. Menzel H-J, Utermann G. Apolipoprotein E phenotyping from serum by Western Blotting. Electrophoresis 1986; 7: 492-495.
28. Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
29. Foster DM, Barrett PHR, Toffolo G, Beltz WF, Cobelli C. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data. J Lipid Res 1993; 34: 2193-2205.
30. Frénais R, Nazih H, Ouguerram K, Maugeais C, Zaïr Y, Bard JM, Charbonnel B, Magot T, Krempf M. In vivo evidence for the role of lipoprotein lipase activity in the regulation of apolipoprotein AI metabolism in patients with type II diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 1962-1967.
31. Iverius PH, Brunzell JD. Human adipose tissue lipoprotein lipase: Changes with feeding and relation to postheparin plasma enzyme. Am J Physiol 1985; 249: E107-E114.
32. Henderson A, Richmond W, Elkeles RS. Hepatic and lipoprotein lipases selectively assayed in postheparin plasma. Clin Chem 1993; 39: 218-223.
33. Pont F, Duvillard L, Verges B, Gambert P. Development of compartmental models in stable-isotope experiments: Application to lipid metabolism. Arterioscler Thromb Vasc Biol 1998; 6: 853-860.
34. Linton MF, Gish R, Hubl ST, Butler E, Esquivel C, Bry WI, Boyles JK, Wardell MR, Young SG. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 1991; 88: 270-281.
35. Zhu Y, Bellosta S, Langer C, Bernini F, Pitas RE, Mahley RW, Assman G, Eckardstein AV. Low dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc Natl Acad Sci USA 1998; 95: 7585-7590.
36. 125l-apolipoprotein E. J Biol Chem 1981; 256: 3963-3968.
37. Blanchette-Mackie EJ, Scow RO. Sites of lipoprotein lipase activity in adipose tissue perfused with chylomicrons: Electron microscope cytochemical study. J Biol Chem 1971; 51: 1-25.
38. Batal R, Tremblay M, Barrett PHR, Jacques H, Fredenrich A, Mamer O, Davignon J, Cohn JS. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res 2000; 41: 706-718.
39. Millar JS, Lichtenstein AH, Dolnikowski GG, Ordovas JM, Schaefer EJ. Proposal of a multicomparmental model for use in the study of apolipoprotein E metabolism. Metabolism 1998; 47: 922-928.
40. Taskinen M-R, Beltz WE Harper I, Fields RM, Schonfeld G, Grundy SM, Howard BV. The effects of non-insulin-dependent diabetes mellitus on VLDL triglyceride and VLDL apoB metabolism: Studies before and after sulfonyl urea therapy. Diabetes 1986; 35: 1268-1277.
41. Weisweiler P, Drosner M, Schwandt P. Dietary effects on very low density lipoproteins in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1982; 23: 101-103.
42. Rensen PCN, Van Berkel TJC. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicronlike triglyceride-rich emulsions in vitro and in vivo. J Biol Chem 1996; 271: 14791-14799.
43. Huang Y, Liu XQ, Rall SCJ, Mahley RW. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipase-mediated lipolysis of triglyceride-rich lipoprotein. J Biol Chem 1998; 273: 17483-17490.
44. Lin CY, Duan HW, Mazzone T. Apolipoprotein E-dependent cholesterol efflux from macrophages: Kinetic study and divergent mechanisms for endogenous vs exogenous apolipoprotein E. J Lipid Res 1999; 40: 1618-1626.
45. Paka L, Kako Y, Obunike JC, Pillarisetti S. Apolipoprotein E containing high density lipoprotein stimulates endothelial production of heparan sulfate rich in biologically active heparin-like domains. A potential mechanism for the anti-atherogenic actions of vascular apolipoprotein E. J Biol Chem 1999; 274: 4816-4823.
46. Riddell DR, Graham A, Owen JS. Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxyde pathway. Implications for vascular disease. J Biol Chem 1997; 272: 89-95.
47. Bach-Ngohou K, Nazih H, Nazih-Sanderson E Zaïr Y, LeCarrer D, Krempf M, Bard JM. Negative and independent influence of apolipoprotein E on C-Reactive protein (CRP) concentration in obese adults. Potential anti-inflammatory role of apoE in vivo. Int J Obes Relat Metab Disord 2001; 25: 1752-1758.